Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- REGULATORY NEWS IN BRIEF
September 30, 2002
- Pharma Delegates Provides Opportunity to Open Communication: Chairman Brrunger
September 30, 2002
- eCTD Reaches Final ICH Step 4 at Washington Meeting
September 30, 2002
- WORLD NEWS IN BRIEF
September 30, 2002
- Scientific Partner System Motivates MRs: Banyu
September 30, 2002
- BULLETIN
September 30, 2002
- Universal Health Insurance System Must Be Maintained at the Peak of Aging
September 30, 2002
- Eiken, Teramecs: Loopamp Real-time Turbidimeter LA-200
September 30, 2002
- Fujisawa Licenses Tacrolimus-coated Stents to Italy
September 30, 2002
- Sysmex: BACTANA to Detect Bacteria in Food
September 30, 2002
- Korosho to Develop Drug Safety Prediction System
September 30, 2002
- BD Japan: BD BBL CultureSwab EZII
September 30, 2002
- Drafting of GL for Physician-led Clinical Trials Progresses
September 30, 2002
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
September 30, 2002
- Ivermectin, Micafungin Recommended for Approval
September 30, 2002
- FDA's Registration Criteria for Drugs to Treat Obesity Outlined: JHSF Seminar
September 30, 2002
- Korosho to Shortly Propose Policy for Health Insurance Reform: Senior Official
September 30, 2002
- b-blockers Not Always More Effective than Ca Antagonists
September 30, 2002
- BUSINESS NEWS IN BRIEF
September 23, 2002
- Takeda to Market Environmental Pollution Reagents via Biosense of Norway
September 23, 2002
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…